about
Do childhood vaccines cause thrombocytopenia?Seroprevalence of hepatitis A infection in a low endemicity country: a systematic reviewApproved but non-funded vaccines: accessing individual protectionUnique roles of a data and safety monitoring board in vaccine safety trials with compressed timelines and urgent implications.High level antibody avidity is achieved in HIV-seropositive recipients of an inactivated split adjuvanted (AS03A) influenza vaccine.Pandemic influenza in Canadian children: a summary of hospitalized pediatric cases.Adverse neurologic reactions after both doses of pandemic H1N1 influenza vaccine with optic neuritis and demyelination.Evaluation of adjuvanted pandemic H1N1(2009) influenza vaccine after one and two doses in young children.Immunogenicity of a half-dose of adjuvanted 2009 pandemic H1N1 influenza vaccine in adults: a prospective cohort study.Strategies for successful rapid trials of influenza vaccine.High-level immunogenicity is achieved vaccine with adjuvanted pandemic H1N1(2009) and improved with booster dosing in a randomized trial of HIV-infected adults.Safety and immunogenicity of 2010-2011 H1N12009-containing trivalent inactivated influenza vaccine in children 12-59 months of age previously given AS03-adjuvanted H1N12009 pandemic vaccine: a PHAC/CIHR Influenza Research Network (PCIRN) study.Comparison of children hospitalized with seasonal versus pandemic influenza A, 2004-2009.Unusual patterns of IgG avidity in some young children following two doses of the adjuvanted pandemic H1N1 (2009) influenza virus vaccine.Thrombocytopenia after immunization of Canadian children, 1992 to 2001.Immunization Monitoring Program, Active: a model of active surveillance of vaccine safety.Postvaccination thrombocytopenia in Canada.Childhood immunization rates in Canada are too low: UNICEF.Knowledge, attitudes, beliefs and behaviours of older adults about pneumococcal immunization, a Public Health Agency of Canada/Canadian Institutes of Health Research Influenza Research Network (PCIRN) investigation.Pertussis vaccine and encephalopathy after the Loveday trial.Progress in the prevention of pneumococcal infection.Advantage of latex agglutination over countercurrent immunoelectrophoresis in the detection of Haemophilus influenzae type b antigen in serum.Safety and effectiveness of the new inactivated hepatitis A virus vaccine.Immunogenicity of 2 doses of HPV vaccine in younger adolescents vs 3 doses in young women: a randomized clinical trial.Evaluation of adverse events after influenza vaccination in hospital personnel.Can Haemophilus influenzae type b-tetanus toxoid conjugate vaccine be combined with diphtheria toxoid-pertussis vaccine-tetanus toxoid?Heterogeneity of rotavirus testing and admitting practices for gastroenteritis among 12 tertiary care pediatric hospitals: Implications for surveillance.Characterization of ampicillin-resistant Haemophilus parainfluenzae.Pediatric immunization for the 1990s.Acellular versus whole-cell pertussis vaccines.Cost effectiveness of infant vaccination for rotavirus in CanadaSerious adverse events associated with bacille Calmette-Guérin vaccine in Canada.Reactogenicity to a live attenuated varicella vaccine in Canadian childrenPopulation-based surveillance of Hib invasive infections in children in British Columbia Alberta and Ontario - 1995 to 1997.Reduced susceptibility to penicillin among pneumococci causing invasive infection in children - Canada, 1991 to 1998.Cortisol, behavior, and heart rate reactivity to immunization pain at 4 months corrected age in infants born very preterm.Seven fatal varicella infections in children were potentially avoidable: A report from IMPACT centres from 2000 to 2005.Questions and answers on immunizationElevated inflammatory mediators in adults with oculorespiratory syndrome following influenza immunization: a public health agency of Canada/Canadian Institutes of Health Research Influenza Research Network Study.Practical questions and answers about childhood immunization
P50
Q24652460-0951909A-14F1-4C8C-A513-C4F275ABDA5FQ24810704-4B92AD21-2E77-4447-9AA5-776C4E3FBAA3Q27022495-9A8E6D4C-F8E7-4735-94CC-0DD1B173ABF6Q30332455-7AB47181-3BC9-41AC-BDBE-A431347A7F34Q30362521-47F55AA3-006F-42D6-8C2A-49D3494A82F7Q30386139-45A4C300-1BDC-4D96-ACF1-FFDA6087F758Q30392316-BD129507-4404-4D51-A42E-FA9A9DAB8164Q30397802-E931066C-2BDB-4116-8741-6497AD81839FQ30405315-1BECD91E-C105-4EE8-A4EB-14F24C99793AQ30406834-E2F864F9-6182-465C-BE46-FF152C5EED8BQ30412595-707AC04A-B7ED-4696-B48B-EAE695846F7DQ30414902-21E9B674-79F9-4B48-B1D3-4858AE9EDC9EQ30420770-1AC3C324-F308-4B7C-8FDA-4384B65CEAAFQ30426236-C7A9B591-DECF-4404-9B48-30E8C10772ACQ33346534-888A0E70-FB4D-49AC-9F5E-F988035DC1C7Q33346534-B86E5C7F-F123-4801-A2D0-2ED4A76BBB59Q33349477-498B9033-B343-4D4E-B492-DA3FEC20DFA1Q33388293-5EBC50DF-0ECB-4AE4-BB47-459DB93428C4Q33642880-6B40C102-B67C-41E0-BC8D-5AEC7885A611Q33713522-C5C0C98A-8D69-4548-8EBD-6BBDDD6DC0EAQ34102509-BE5281F3-69D8-40CD-909E-D602A5F27696Q34117676-AF18EAF5-8056-44BF-837B-64004AFAE895Q34274431-0AB18BB5-7870-4339-9D55-B323B6C014C9Q34278232-20393373-8067-4D8F-8EE2-37661A1D3274Q34342056-058D5668-8DE1-4894-A650-3A00375ADB8FQ34577510-29BB8C92-8B0C-48F4-8B12-74E0FE9E3729Q34706329-8A690BD3-B4DD-439F-AECC-AA4AB5DDDCFDQ34789779-D2BB7EB4-89A5-4E71-AB0F-F0169E47B72AQ35675664-D2ECB659-FC5D-444F-B05D-73B12ED4A626Q35839193-0460BF34-9295-43C2-B69A-B4B6FC13E568Q35893229-0D402FF5-8DD9-4BFA-8919-C8CD31BBC6AAQ36111776-D39167CB-6538-4943-8C2F-648B2BA9290FQ36149521-7D8F1AFC-0074-463E-8B3D-951AAC44EA85Q36170149-6195BD62-1DBB-4C56-834B-710299353E70Q36170176-8C84EA06-89D6-4F9D-928B-082EFD4C62DAQ36170388-FD9527E1-5397-497B-B99B-6902F012CFD6Q36802994-AC299A42-023A-46EE-967C-7DF8CF8A7AF7Q36860505-D0C2F10F-60AD-4246-AD5C-DE655D587B26Q36860604-03CEE737-FEC5-4802-A763-DF330AD2F104Q37124705-07735B96-BC83-4711-B06B-F471F808AEAD
P50
description
hulumtues
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
David W Scheifele
@ast
David W Scheifele
@en
David W Scheifele
@es
David W Scheifele
@nl
David W Scheifele
@sl
type
label
David W Scheifele
@ast
David W Scheifele
@en
David W Scheifele
@es
David W Scheifele
@nl
David W Scheifele
@sl
altLabel
David W. Scheifele
@en
prefLabel
David W Scheifele
@ast
David W Scheifele
@en
David W Scheifele
@es
David W Scheifele
@nl
David W Scheifele
@sl
P106
P21
P31
P496
0000-0001-6078-7843